The Readout Loud

300 Episodes

1. 298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

   Published: 3/14/2024
2. 297: VC turmoil, GLP-1 competition, & the war on recovery

   Published: 3/7/2024
3. 296: Legal insider trading, booming biotech stocks, & the next GLP-1

   Published: 2/29/2024
4. 295: Humira’s legacy, CEO symbolism, and genomic surgery

   Published: 2/22/2024
5. 294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking

   Published: 2/15/2024
6. 293: AI in medicine, detangling hype, and Icelandic DNA

   Published: 2/8/2024
7. 292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon

   Published: 2/1/2024
8. 291: The plight of the VC, Gilead's latest setback, & more M&A

   Published: 1/25/2024
9. 290: Biotech layoffs, slumping stocks, and a 2024 preview

   Published: 1/18/2024
10. 289: Live! From #JPM24

    Published: 1/11/2024
11. 287: 2023 in review, CEO report cards, and a look at the year ahead

    Published: 12/21/2023
12. 286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future

    Published: 12/14/2023
13. 285: CRISPR history, biotech struggles, & a big week for deals

    Published: 12/7/2023
14. 284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job

    Published: 11/30/2023
15. 283: A CRISPR milestone, algorithms amok, & biotech mixology

    Published: 11/16/2023
16. From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?

    Published: 11/13/2023
17. 282: Lilly’s obesity drug, the power of radiation, & a biotech implosion

    Published: 11/9/2023
18. 281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO

    Published: 11/2/2023
19. 280: ESMO highlights, Roivant's big deal, & biotech VC on the rise

    Published: 10/26/2023
20. 279: Live from the 2023 STAT Summit

    Published: 10/19/2023